Results 211 to 220 of about 1,459,532 (261)

Type 2 inflammation in cystic fibrosis is a predictor of mortality and targeted with CFTR modulator therapy. [PDF]

Allergy
Cook DP, Wu AY, Thomas CM, Hamilton RG, Peebles RS, Kerchberger VE.   +5 more
europepmc   +1 more source

Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium. [PDF]

Heliyon
Jarosz-Griffiths HH, Caley LR, Lara-Reyna S, Savic S, Clifton IJ, McDermott MF, Peckham DG.   +6 more
europepmc   +1 more source

Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy. [PDF]

BMJ Open Respir Res
Burgel PR, Ballmann M, Drevinek P, Heijerman H, Jung A, Mainz JG, Peckham D, Plant BJ, Schwarz C, Taccetti G, Smyth A.   +10 more
europepmc   +1 more source

Qualitative study exploring the views and perceptions of parents/carers of young children with CF regarding the introduction of CFTR modulator therapy (The REVEAL study; PaRents pErspectiVEs of KAftrio in chiLdren aged 2-5). [PDF]

BMJ Open Respir Res
Davies SH, Wade F, Fogg H, Walsh A, Southern KW.   +4 more
europepmc   +1 more source

Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis - a real-life insight. [PDF]

Mol Cell Pediatr
Fabricius D, Knieling T, Zurmuehl N, Makedon L, Freihorst J, Schmidt H, Bode S.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®

Journal of Cystic Fibrosis, 2023
The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta®, Kaftrio®) significantly improve outcomes, including survival in a broad range of cystic fibrosis patients.
Smita Pakhale, Salmaan Kanji, Kristy Wong   +2 more
exaly   +2 more sources

Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis

Journal of Cystic Fibrosis
BACKGROUND People with cystic fibrosis (PwCF) have experienced substantial improvements in health following use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies. However, less is known about how modulator therapies impact
Aricca D Van Citters, Enid Aliaj, Cynthia D Brown   +2 more
exaly   +2 more sources

The psychological implications and health risks of cystic fibrosis pre- and post- CFTR modulator therapy [PDF]

Chronic Illness, 2022
Objectives Cystic Fibrosis (CF) care is entering a period of personalised medicine with the emergence of CF transmembrane conductance regulator (CFTR) modulator therapies. Anecdotally individuals are reporting life-changing effects of modulator therapies,
R. Keyte, S. Kauser, M. Mantzios, H. Egan   +3 more
semanticscholar   +2 more sources

A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants [PDF]

Journal of Personalized Medicine, 2021
Trikafta, a triple-combination drug, consisting of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor) and the gating potentiator VX-770 (ivacaftor) provided unprecedented clinical benefits for patients with the most common cystic fibrosis (CF ...
Guido Veit, Tony Velkov, Haijin Xu
exaly   +2 more sources

CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis.

The Lancet, 2023
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a new era of cystic fibrosis management has emerged-one in which ...
J. Taylor-Cousar, Paul D. Robinson, M. Shteinberg, Damian G. Downey   +3 more
semanticscholar   +1 more source